Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY Endometrial01
CTR20244095Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, rilvegostomig, pembrolizumab in endometrial cancer (EC), sponsored by AstraZeneca. Started Jul 2025; status: active.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20244095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244095.